TRVI — Trevi Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.64bn
- $1.44bn
- 46
- 24
- 94
- 55
Annual income statement for Trevi Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 32.5 | 32.5 | 29.9 | 33.9 | 51.5 |
| Operating Profit | -32.5 | -32.5 | -29.9 | -33.9 | -51.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -32.8 | -34 | -29.2 | -29.1 | -47.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -32.8 | -33.9 | -29.2 | -29.1 | -47.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -32.8 | -33.9 | -29.2 | -29.1 | -47.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -32.8 | -33.9 | -29.2 | -29.1 | -47.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.81 | -1.49 | -0.452 | -0.293 | -0.47 |